GlaxoSmithKline plc (ADR) (GSK), Sanofi SA (ADR) (SNY), Theravance Inc (THRX): This Week in Biotech

Finally, Bayer and Algeta received a once-in-a-blue-moon FDA approval for Xofigo (previously Radium-223 dichloride) to treat metastatic castration-resistant prostate cancer that’s spread to bones but no other organs because of surgical therapies aimed at lowering testosterone. The FDA approved Xofigo three months early and, in trials, extended PFS to 14 months, as compared with 11.2 months for the placebo.

While you can certainly make huge gains in biotech and pharmaceuticals, the best investing approach is to choose great companies and stick with them for the long term. The Motley Fool’s free report “3 Stocks That Will Help You Retire Rich” names stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.

The article This Week in Biotech originally appeared on and is written by Sean Williams.

Fool contributor Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong.Try any of our Foolish newsletter services free for 30 days. We Fools don’t all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.